References
- 1. Lameire N, Van Biesen W, Vanholder R. The role of peritoneal dialysis as first modality in an integrative approach to patients with end –stage renal disease. Peritoneal Dialysis International. 2000;20(2):S134-141.
- 2. Li PK, Szeto CC, Piraino B, et al. ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment. Perit Dial Int. 2016;36:481-508.10.1145/2999572.2999609
- 3. Holley JL, Praino BM. Complications of peritoneal dialysis: Diagnosis and management. Semin Dial. 1990;3:245.
- 4. Woodrow G, Turney JH, Brownjohn AM. Technique failure in peritoneal dialysis and its impact on patient survival. Perit Dial Int. 1997;17:360.
- 5. Perez Fontan M, Rodriguez-Carmona A, Garcia-Naveiro R, et al. Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int. 2005;25:274.
- 6. Akoh JA. Peritoneal dialysis associated infections: An update on diagnosis and management. World J Nephrol. 2012;1(4):106–122.
- 7. MacArthru RD. Branhamella Catarrhalis peritonitis in two continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1990;10:169–71.
- 8. Dadone C, Redaelli B. Branhamella Catarrhalis peritonitis in CAPD: An avoidable complication. Perit Dial Int. 1991;11:185.
- 9. Contreras MR, Ash SR, Swick SD, Grutzner J. Peritonitis due to Moraxella Catarrhalis(Branhamella) in a diabetic patient receiving peritoneal dialysis. South Med J. 1993;86:589–90.10.1097/00007611-199305000-00023
- 10. Ragnaud JM, Bezian MC, Marceau DM, Wone C. Treatment of peritonitis in continuous ambulatory peritoneal dialysis with intraperitoneal ceftriaxone. Pathol Biol. 1988;36(5):552–56.
- 11. Fandos JMG, Manez MB. Peritonitis Due to Moraxella Non Liquefaciens. Perit Dial Int. 2014; 34(6): 674–675.
- 12. Badrising S, Bakker L, Lobatto S, Van Es A. Peritonitis in a Peritoneal Dialysis Patient Due to Rhizobium radiobacter and Moraxella osleonsis: Case Report and Literature Review. Perit Dial Int. 2014; 34(7): 813–815.
- 13. Sadjadi SA, Obedoza P, Annamarju P. Moraxella Catarrhalis peritonitis. Am J Case Rep. 2012;13:19–21.
- 14. Verduin CM, Hol C, Fleer A, at al. Moraxella catarrhalis: from emerging to established pathogen. Clinical Microbiology Reviews 2002;15(1):125-144.10.1128/CMR.15.1.125-144.2002
- 15. Ryan KJ, Ray CG. Sherris Medical Microbiology: An Introduction to Infectious Disease. 4th ed. New York, McGraw-Hill; 2004.
- 16. Garrity GM, Brenner DJ, Krieg NR and Staley JT (Eds.). Bergey’s Manual of Systematic Bacteriology. 2nd ed. New York: Springer; 2005.
- 17. Murray PR, Baron EJ, Jorgensen JH, Landry ML and Pfaller MA (Eds.). Manual of Clinical Microbiology. 9th ed. Washington: ASM Press; 2007.
- 18. Buchanan BK. Moraxella, branhamella, Kingella and Aeikenella. In: Balows A. and Duerden BI (Eds). Topley and Wilson’s Microbiology and Microbial Infections. 1998. P1139-46.
- 19. Tritton D, Watts T, Sieratzki JS. Peri-orbital cellulitis and sepsis by Branhamella catarrhalis. Eur J Pediatr. 1998;157(7):611-2.
- 20. Abdolrasouli A, Amin A, Baharsefat M, et al. Moraxella catarrhalis associated with acute urethritis imitating gonorrhoea acquired by oral-genital contact. Int J STD AIDS. Aug. 2007;18(8):579-80.
- 21. Jorgensen JH, Doern GV, Maher LA, et al. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrobial Agents and Chemotherapy. 1990;34(11):2075-2080.